Filtered By:
Therapy: Immunotherapy
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 258 results found since Jan 2013.
Self-amplified ROS production from fatty acid oxidation enhanced tumor immunotherapy by atorvastatin/PD-L1 siRNA lipopeptide nanoplexes
Biomaterials. 2022 Nov 3;291:121902. doi: 10.1016/j.biomaterials.2022.121902. Online ahead of print.ABSTRACTDespite the important role of reactive oxygen species (ROS) in battling cancer, ROS production with current approaches has been severely limited by the deficiency of oxy-substrates in tumor microenvironment. Herein, an atorvastatin (Ato)-catalytic self-amplified approach was utilized for sustainable ROS production and enhancing anti-tumor efficacy of PD-L1 silencing. A C18-pArg8-ss-pHis10 lipopeptide based self-assembled nanoplexes was developed to co-encapsulate AMP-activated protein kinase (AMPK) activator of Ato a...
Source: Biomaterials - November 13, 2022 Category: Materials Science Authors: Yan Gao Zilin Song Li Jia Yi Tang Chengcheng Wang Xiuli Zhao Haiyang Hu Dawei Chen Mingxi Qiao Source Type: research
PAIP2 is a potential diagnostic and prognostic biomarker of breast cancer and is associated with immune infiltration
Breast cancer is the second highest incidence of cancer in the world. It is of great significance to find biomarkers to diagnose breast cancer and predict the prognosis of breast cancer patients. PAIP2 is a poly (A) -binding protein interacting protein that regulates the expression of VEGF. However, the possible role of PAIP2 in the progression of breast cancer is still unknown. RT-qRCR and Western blotting were used to verify the expression of PAIP2 in breast cancer cells and normal breast cells. The data of breast cancer samples were obtained in the TCGA database and the HPA database to analyze the expression of PAIP2 in...
Source: Frontiers in Genetics - November 10, 2022 Category: Genetics & Stem Cells Source Type: research
p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target
CONCLUSION: Our research may provide a novel potential target for TNBC.PMID:36352176 | DOI:10.1007/s11033-022-08047-z
Source: Mol Biol Cell - November 9, 2022 Category: Molecular Biology Authors: Siyu Deng Mengna Wang Chenglong Wang Yan Zeng Xue Qin Yiwen Tan Bing Liang Youde Cao Source Type: research
Cancers, Vol. 14, Pages 5363: Electroporation in Head-and-Neck Cancer: An Innovative Approach with Immunotherapy and Nanotechnology Combination
i
Marco Benazzo
Squamous cell carcinoma is the most common malignancy that arises in the head-and-neck district. Traditional treatment could be insufficient in case of recurrent and/or metastatic cancers; for this reason, more selective and enhanced treatments are in evaluation in preclinical and clinical trials to increase in situ concentration of chemotherapy drugs promoting a selectively antineoplastic activity. Among all cancer treatment types (i.e., surgery, chemotherapy, radiotherapy), electroporation (EP) has emerged as a safe, less invasive, and effective approach for cancer treatment. Reversible EP, using an...
Source: Cancers - October 31, 2022 Category: Cancer & Oncology Authors: Silvia Pisani Giulia Bertino Adriele Prina-Mello Laura Deborah Locati Simone Mauramati Ida Genta Rossella Dorati Bice Conti Marco Benazzo Tags: Review Source Type: research
Lipoprotein(a) lowering and cardiovascular risk reduction by PCSK9 inhibitors
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition augments recirculation of the low-density lipoprotein (LDL) receptor to the hepatocyte surface [1], thereby lowering atherogenic particles through accelerated clearance of circulating LDL cholesterol (LDL-C). This observation led to several strategies to inhibit PCSK9, including monoclonal antibodies (evolocumab and alirocumab), small-molecule inhibitors specific to PCSK9, small interfering RNA (siRNA) molecules (inclisiran), antisense oligonucleotides, immunotherapy with a PCSK9 peptide vaccine, and CRISPR/Cas9 editing of PCSK9.
Source: Atherosclerosis - October 21, 2022 Category: Cardiology Authors: Maya S. Safarova, Iftikhar J. Kullo Tags: Editorial Source Type: research
Increased Expression of NXPH4 Correlates with Immune Cell Infiltration and Unfavorable Prognosis in Hepatocellular Carcinoma
This study suggested that the upregulation of NXPH4 is associated with adverse prognosis and immune cell infiltration in HCC. NXPH4 could be a novel biomarker of unfavorable prognosis and an underlying target for immunotherapy in HCC.PMID:36245978 | PMC:PMC9560829 | DOI:10.1155/2022/5005747
Source: Journal of Oncology - October 17, 2022 Category: Cancer & Oncology Authors: Qin Tang Yue-Ming Chen Mei-Mei Shen Wen Dai Hang Liang Jun-Nan Liu Jian Gao Source Type: research
Targeting tumor hypoxia inhibits aggressive phenotype of dedifferentiated thyroid cancer
CONCLUSIONS: Hypoxia score serves as a significant indicator for dedifferentiation status, prognoses and immunotherapeutic response predicted by Tumor Immune Dysfunction and Exclusion in DDTC patients. Targeting hypoxia by ACF is useful to alleviate aggressive phenotype of ATC in pre-clinical model of DDTC.PMID:36190930 | DOI:10.1210/clinem/dgac548
Source: The Journal of Clinical Endocrinology and Metabolism - October 3, 2022 Category: Endocrinology Authors: Ben Ma Shishuai Wen Yi Luo Tingting Zhang Yichen Yang Cenkai Shen Yan Zhang Qinghai Ji Ning Qu Yu Wang Source Type: research
Chitosan coated pH/redox-responsive hyaluronic acid micelles for enhanced tumor targeted co-delivery of doxorubicin and siPD-L1
Int J Biol Macromol. 2022 Sep 29:S0141-8130(22)02184-5. doi: 10.1016/j.ijbiomac.2022.09.245. Online ahead of print.ABSTRACTThe complex tumor microenvironment (TME) makes it difficult for single chemotherapy to achieve satisfactory therapeutic effects. Here, chitosan-coated hyaluronic acid micelles (R/C/D@HAssOA) that co-delivers doxorubicin (DOX) and programmed death-ligand 1 small interfering RNA (siPD-L1) are developed to enhance anti-tumor effect by combination of immunotherapy and chemotherapy. The pH/reduction dual-responsive co-delivery micelles R/C/D@HAssOA are spherical particles about 180 nm, and have good drug lo...
Source: International Journal of Biological Macromolecules - October 2, 2022 Category: Biochemistry Authors: Panpan Song Zhongxia Lu Tianze Jiang Wenwei Han Xiangyan Chen Xia Zhao Source Type: research
Construction of PEI ‐EGFR‐PD‐L1‐siRNA dual functional nano‐vaccine and therapeutic efficacy evaluation for lung cancer
ConclusionOur constructed lipid nanoparticles of tumor targeted therapy gene siRNA combination had the ability to target cells in vitro and downregulate the expression of PD-L1, realizing the tumor-specific expression of immune-stimulating cytokines, which is a highly efficient and safe targeted therapy nano-vaccine.
Source: Thoracic Cancer - September 19, 2022 Category: Cancer & Oncology Authors: Guixue Yang,
Dong Zhou,
Yin Dai,
Yanqi Li,
Jiang Wu,
Quanxing Liu,
Xufeng Deng Tags: ORIGINAL ARTICLE Source Type: research
Cancers, Vol. 14, Pages 4438: Pan-Cancer Analysis of Pentraxin 3: A Potential Biomarker of COVID-19
Zhong Wu
Pentraxin 3 (PTX3), a potential biomarker of the severity and mortality of COVID-19 patients, is aberrantly expressed in human tumors. However, a comprehensive pan-cancer analysis of PTX3 remains to be elucidated. PTX3 data profiles and clinical information in TCGA cancers were obtained from different public databases to clarify the expression levels, genetic alterations, prognostic significance, underlying mechanisms, and the predicted role in immunotherapy of PTX3 across TCGA cancers. Our analyses showed that PTX3 was aberrantly expressed in most tumors and was significantly related to prognosis and tumor s...
Source: Cancers - September 13, 2022 Category: Cancer & Oncology Authors: Zijian Zhou Xuan Zhou Yuanyuan Yang Lujia Wang Zhong Wu Tags: Article Source Type: research
Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood
AbstractImmune checkpoint blockade therapy is a treatment option of various metastatic cancer diseases including renal cell carcinoma (RCC). Approved antibody drugs target the co-inhibitory signaling of Programmed Cell Death Ligand-1 (PD-L1) and its receptor Programmed Cell Death-1 (PD-1). The combined evaluation of PD-L1 and PD-1 at the mRNA and protein levels in tumor tissue with differentiation of tumor and immune cells as well as of soluble forms (sPD-L1) and (sPD-1) in blood is of basic interest in ass essing biomarker surrogates. Here, we demonstrate that PD-L1 determined as fraction of stained tumor cells (TPS-sco...
Source: Cancer Immunology, Immunotherapy - September 10, 2022 Category: Cancer & Oncology Source Type: research
Exosomes carrying immune checkpoints, a promising therapeutic approach in cancer treatment
AbstractExosomes are a subgroup of extracellular vesicles generated by distinct cells. Tumor-derived extracellular vesicles convey immunological checkpoint molecules. TEXs as critical mediators in tumor development, metastasis, and immune escape have recently become the focus of scientific research. Exosomes are involved in the regulation of the immune system. Exosomes interact with target cells in the tumor microenvironment, changing their function based on the cargo they contain. Exosomal immune checkpoints might be exploited to track tumor immune evasion, treatment response, and patient prognosis while enhancing tumor c...
Source: Medical Oncology - September 7, 2022 Category: Cancer & Oncology Source Type: research
